J&J's Stock Performance: A Mixed Bag
Are Wall Street Analysts Fond of Johnson & Johnson's Shares?
Johnson & Johnson's (JNJ) stock performance has been somewhat lackluster compared to the S&P 500, but it's still outperforming in certain areas. As of the latest data, JNJ's total return over the past year was 6.22% compared to the S&P 500's return of 10.65%[3]. However, JNJ has shown more vigor this year, rising by 7.49% year-to-date in 2025, while the S&P 500 has dipped by -8.1%[5].
Regarding the Health Care Select Sector SPDR Fund (XLV), JNJ is a significant player in the healthcare sector, so its performance can have an impact on the broader sector. Precise data for comparison isn't provided in the search results, but JNJ's outperformance relative to the S&P 500 indicates a strong showing despite some stumbles.
Analysts Weigh In: Earnings Growth Expectations
The specifics about JNJ's adjusted EPS growth for the fiscal year ending in December 2025 aren't spelled out in the provided data. However, JNJ's recent earnings reports point towards a positive trend, with the company beating earnings expectations in its Q1 2025 report[5]. Over the last four quarters, JNJ has consistently outdone consensus EPS estimates[5], suggesting a robust earnings performance. Analysts will keep a close eye on future earnings calls for insights on financial expectations.
If you're looking for more accurate adjusted EPS growth expectations, you should seek out recent analyst reports or financial projections from reliable financial services.
Due to Johnson & Johnson's (JNJ) consistent beating of earnings expectations in recent quarters, investors may find attractive opportunities for investing in the company's finance sector. Business analysts have expressed optimism about JNJ's earnings growth prospects for the fiscal year ending in December 2025, making it a potential area for strategic business decisions and further investments.
